1. Home
  2. FEIM vs ALLO Comparison

FEIM vs ALLO Comparison

Compare FEIM & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FEIM
  • ALLO
  • Stock Information
  • Founded
  • FEIM 1961
  • ALLO 2017
  • Country
  • FEIM United States
  • ALLO United States
  • Employees
  • FEIM N/A
  • ALLO N/A
  • Industry
  • FEIM Electrical Products
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FEIM Industrials
  • ALLO Health Care
  • Exchange
  • FEIM Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • FEIM 291.0M
  • ALLO 252.9M
  • IPO Year
  • FEIM N/A
  • ALLO 2018
  • Fundamental
  • Price
  • FEIM $27.13
  • ALLO $1.13
  • Analyst Decision
  • FEIM
  • ALLO Strong Buy
  • Analyst Count
  • FEIM 0
  • ALLO 10
  • Target Price
  • FEIM N/A
  • ALLO $8.88
  • AVG Volume (30 Days)
  • FEIM 322.7K
  • ALLO 3.2M
  • Earning Date
  • FEIM 09-11-2025
  • ALLO 11-06-2025
  • Dividend Yield
  • FEIM N/A
  • ALLO N/A
  • EPS Growth
  • FEIM 264.74
  • ALLO N/A
  • EPS
  • FEIM 2.27
  • ALLO N/A
  • Revenue
  • FEIM $68,546,000.00
  • ALLO N/A
  • Revenue This Year
  • FEIM $12.60
  • ALLO N/A
  • Revenue Next Year
  • FEIM $19.17
  • ALLO $100.00
  • P/E Ratio
  • FEIM $11.97
  • ALLO N/A
  • Revenue Growth
  • FEIM 18.30
  • ALLO N/A
  • 52 Week Low
  • FEIM $11.71
  • ALLO $0.86
  • 52 Week High
  • FEIM $34.84
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • FEIM 41.20
  • ALLO 47.98
  • Support Level
  • FEIM $30.71
  • ALLO $1.09
  • Resistance Level
  • FEIM $34.84
  • ALLO $1.17
  • Average True Range (ATR)
  • FEIM 2.23
  • ALLO 0.07
  • MACD
  • FEIM -0.43
  • ALLO 0.01
  • Stochastic Oscillator
  • FEIM 0.13
  • ALLO 33.33

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: